Clinical Observation of Hyperlipemia Treated by Pushen Capsule

OBJECTIVE To investigate the clinical effective of patent Chinese drug Pushen Capsule treating hyperlipemia， and to demonstrate its function of lipid regulation. METHODS 120 cases of hyperlipemia patients were randomly divided into 3 groups (40 cases each). Group A was the Pushen capsule group and taken Pushen capsule (4 pills of each time， three times a day); Group B was the Rosuvastatin calcium tablet group (Crestor group) taken Crestor 10mg each night; Group C was combined treatment group and taken all the drugs of the upper groups. After 6 and 10 weeks， the lipemia regulation function of each groups were investigated. RESULTS Compare with before the treatment， each groups' TC/TG/TDL-C were declined remarkably after 6 and 10 weeks treatment (P<0.01)， and HDL-C were risen prominently (P<0.01). 10 weeks total effective rate comparison shows that Groups A and C were higher than B on TG， group B and C were higher than A on TC/ LDL-C. The differences were significant (P<0.05). There was no significant difference on HDL-C in three groups (P>0.05). Adverse reactions during treatment of three groups were mild. CONCLUSION total effective rate of declining TG of Pushen capsule Group is higher than Crestor Group， and combined treatment group is more effective than Pushen capsule only or Crestor only group on treating hyperlipemia. Crestor's total effective rate is higher than Pushen capsule group on lower TC/LDL-C.